ClinicalTrials.gg
Not yet recruitingNCT07939685Updated Nov 16, 2026

Entinostat + R-CHOP in Newly Diagnosed MYC/BCL2 Double-Expressor DLBCL: Phase II Trial

A Phase 2 interventional study of Entinostat+R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL), sponsored by Shu Zhao. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Shu Zhao · Phase 2, Interventional, and Treatment

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to evaluate the efficacy and safety of entinostat combined with the R-CHOP regimen in patients with newly diagnosed MYC/BCL2 Double-Expressor DLBCL.

02

Conditions studied

  • Diffuse Large B-Cell Lymphoma (DLBCL)
03

In context

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 357 are open to participants now.

This study's planned enrollment of 30 is below the median of 45 across 1,499 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

This is the only study on the registry with Shu Zhao as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Understand and voluntarily sign the form; 2. Aged ≥18 years and ≤80 years, male or female; 3. No prior treatment for DLBCL, including chemotherapy, targeted therapy, immunotherapy, local radiotherapy for lymphoma (except local radiotherapy for relief of tumor-related symptoms), and surgical treatment (except tumor or pathological and surgical resection not intended for lymphoma); 4. Histopathologically confirmed diagnosis (all of the following criteria must be met simultaneously):

    1. Diffuse large B-cell lymphoma with CD20 positivity;
    2. MYC/BCL2 double-expressor: concurrent expression of MYC and BCL2 per WHO immunohistochemistry criteria: MYC ≥40%, BCL2 ≥50%;
    3. Not double-hit or triple-hit: FISH testing shows absence of MYC and BCL2 rearrangement, MYC and BCL6 rearrangement, or MYC, BCL2 and BCL6 rearrangement.

    5. At least one 18F-fluorodeoxyglucose (18FDG) PET-CT-positive lesion per the Lugano 2014 criteria for Hodgkin and non-Hodgkin lymphomas; 6. International Prognostic Index (IPI) score >1; 7. performance status score of 0, 1 or 2; 8. Laboratory values at screening meet the following criteria, unless the investigator determines the abnormality is secondary to lymphoma (no corrective or supportive therapy for these parameters administered within 2 weeks prior to assessment):

    1. Hematology: (Hb) ≥90 g/L, (ANC) ≥1.5×10⁹/L, count (PLT) ≥90×10⁹/L;
    2. Chemistry: serum creatinine (Cr) ≤1.5 × (ULN); total (TBIL) ≤1.5 × ULN; (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN (≤5 × ULN in cases with hepatic involvement).

    9. Investigator-estimated of at least 6 months.

Exclusion criteria

Exclusion Criteria:

  • 1. With central nervous system (CNS) or ; 2. Previous or concurrent primary CNS DLBCL, primary mediastinal (thymic) large B-cell lymphoma, primary effusion DLBCL, B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma (grey zone lymphoma), primary cutaneous DLBCL, indolent lymphoma, Burkitt lymphoma, EBV-positive mucocutaneous ulcer, DLBCL associated with chronic inflammation, lymphomatoid granulomatosis, intravascular large B-cell lymphoma, ALK-positive large B-cell lymphoma, plasmablastic lymphoma, HHV8-positive DLBCL, NOS, or primary testicular lymphoma; 3. Transformed lymphoma, i.e., transformed from other lymphoma subtypes such as follicular lymphoma, marginal zone B-cell lymphoma, and chronic lymphocytic leukemia/small B-cell lymphoma; 4. Prior history of organ transplantation or hematopoietic stem cell transplantation; 5. Patients who plan to receive consolidative hematopoietic stem cell transplantation after achieving complete response (CR) with treatment; 6. Previous or concurrent other malignant neoplasms, except for adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, and carcinoma in situ of the cervix; 7. Received cytotoxic agents for other diseases (e.g., rheumatoid arthritis) within 5 years prior to the first dose, or prior exposure to any anti-CD20 antibody; 8. Received any monoclonal antibody within 3 months prior to the first dose; 9. Participated in other interventional clinical trials within 3 months prior to the first dose; 10. History of severe or allergic reactions to humanized or murine monoclonal antibodies, or known sensitivity or allergic reaction to murine-derived products; 11. to any component of the CHOP regimen; 12. use at a dose >30 mg/day prednisone or equivalent for indications other than control of lymphoma-related symptoms. Eligible scenarios must meet the corresponding requirements below:

    1. If receiving corticosteroid treatment at a dose ≤30 mg/day prednisone or equivalent, documented stable dose must be available for at least 4 weeks before the start of Cycle 1;
    2. If urgent glucocorticoid therapy is required to control lymphoma symptoms before the first dose, up to 100 mg prednisone or equivalent may be administered for a maximum of 7 days, and all tumor assessments must be completed before initiation of glucocorticoid therapy.

    13. History of severe peripheral nervous system or central nervous system disorders, e.g., progressive multifocal leukoencephalopathy; 14. Uncontrolled or significant cardiovascular disease, including:

    1. (NYHA) Class II or higher congestive heart failure, unstable angina, myocardial infarction within 6 months before the first study drug administration, or arrhythmia requiring treatment at screening, or (LVEF) \<50%;
    2. Primary cardiomyopathy (e.g., dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, restrictive cardiomyopathy, unclassified cardiomyopathy);
    3. History of prolongation, or QTc >470 ms (female) / >450 ms (male) at screening;
    4. Symptomatic coronary artery disease requiring pharmacotherapy at screening;
    5. Other cardiovascular diseases judged by the investigator to render the subject ineligible.

    15. History of interstitial lung disease (ILD) such as pulmonary fibrosis, or evidence of ILD on baseline chest CT or MRI; 16. Clinically significant gastrointestinal abnormalities that may affect drug intake, transit or absorption (e.g., inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy; 17. History of deep vein thrombosis or pulmonary embolism; 18. Active bleeding within 2 months before the first dose, or current anticoagulant use (e.g., warfarin, phenprocoumon), or definite bleeding diathesis judged by the investigator (e.g., esophageal varices at bleeding risk, local active ulcerative lesions, fecal occult blood >2+), except bleeding deemed by the investigator to be caused by lymphoma itself (e.g., gastrointestinal bleeding secondary to gastrointestinal lymphoma); 19. High-risk surgery on vital organs performed within 6 weeks prior to screening, or other conditions with poor surgical wound healing as judged by the investigator; 20. Active infection, active or uncontrolled , infection, /AIDS (Acquired Immune Deficiency Syndrome) or other severe infectious diseases (Note: active infection refers to infection requiring systemic treatment; qualitative testing is prioritized for HBV/HCV/HIV, with quantitative testing performed as needed; subjects are eligible only after HBV DNA becomes negative after treatment); 21. Any psychiatric or cognitive disorder that may impair understanding of the form, adherence to study procedures and study compliance; 22. Illicit drug use or alcohol abuse; 23. Female subjects of or male subjects whose female partners are of childbearing potential who are unwilling or unable to use effective throughout the treatment period of this trial and for 12 weeks after the last dose of entinostat or 12 months after the last dose of rituximab, whichever occurs later [Women of childbearing potential include any female who has experienced menarche and has not undergone successful permanent sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or reached menopause]; pregnant or lactating women; 24. Other conditions judged by the investigator to make the subject unsuitable for participation in this trial.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Entinostat+R-CHOP

    Drug: Entinostat+R-CHOP

Interventions

  • DrugEntinostat+R-CHOP

    Patients were receive oral entinostat(3mg on days 1, 8, and 15 of each 21-day cycle) plus 6 cycles of R-CHOP. Patients with a complete response after combination therapy received entinostat maintenance up to 24 weeks.

06

What researchers measure

Primary outcomes

  1. Complete Clinical Rate(CCR)

    Defined as the proportion of subjects with measurable disease who achieve CR.

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Safety of Entinostat when combined with R-CHOP

    All adverse events occurring during or after the first treatment will be summarized by treatment arm and NCI CTCAE grade.

    Time frame: Up to approximately 3 years

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2027, 13 months later.

Of 210 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 13 months is below that.

Counting every sponsor, half of 264 studies reached it within 53 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 30, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07939685
Lead sponsor
Shu Zhao
Collaborators
Eddingpharm (Zhuhai) Co., Ltd.
Responsible party
Shu Zhao (Chief Physician, The Third Affiliated Hospital of Harbin Medical University) — Sponsor-investigator
First posted
Nov 16, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 16, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion